OPDIVO (nivolumab), anti-PD1 antibody

High clinical benefit for the treatment of advanced-stage clear cell kidney cancer or kidney cancer with a clear cell contingent after prior anti-VEGF therapy failure and moderate clinical added value compared to everolimus

• OPDIVO has been granted a marketing authorisation for monotherapy treatment of adults suffering from advanced renal cell carcinoma after prior treatment.
• Its superiority has been established over everolimus in terms of overall survival in patients with clear cell kidney cancer.
• It is a second-line treatment after failure of prior tyrosine kinase treatment.

-